{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:39:38Z","timestamp":1791315578543,"version":"4.3.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clim.2023.109275","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:51:40Z","timestamp":1677757900000},"page":"109275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["JAK inhibition for CD3\u2212 CD4+ lymphocytic-variant hypereosinophilic syndrome"],"prefix":"10.1016","volume":"251","author":[{"given":"Stanislas","family":"Faguer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Groh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Vergez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Hunault-Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Renaudineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2023.109275_bb0005","first-page":"1086","article-title":"CD3\u2013CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder","volume":"100","author":"Lef\u00e8vre","year":"2015","journal-title":"Haematologica."},{"key":"10.1016\/j.clim.2023.109275_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated with CD3\u2212CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109275_bb0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2023.109275_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109275_bb0025","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical profile and treatment in hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2023.109275_bb0030","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2023.109275_bb0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109275_bb0040","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clim.2023.109275_bb0045","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2023.109275_bb0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2023.109275_bb0055","series-title":"Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis","author":"Williams","year":"2023"},{"key":"10.1016\/j.clim.2023.109275_bb0060","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/leu.2015.280","article-title":"Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia","volume":"29","author":"Bilori","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.clim.2023.109275_bb0065","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109275_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.10.036","article-title":"Janus kinase 1\/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses","volume":"133","author":"Ashino","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109275_bb0075","doi-asserted-by":"crossref","first-page":"40091","DOI":"10.1074\/jbc.M111.273482","article-title":"Three lysine residues in the common \u03b2 chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling","volume":"286","author":"Lei","year":"2011","journal-title":"J. Biol. Chem."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623000542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623000542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:11:17Z","timestamp":1761495077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623000542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":15,"alternative-id":["S1521661623000542"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109275","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibition for CD3\u2212 CD4+ lymphocytic-variant hypereosinophilic syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109275"}}